Akorn Margine di profitto
Cos'è Margine di profitto di Akorn?
Margine di profitto di Akorn, Inc. è -33.23%
Qual è la definizione di Margine di profitto?
Il margine di profitto è una misura della redditività e viene calcolato rilevando l'utile netto come percentuale delle entrate.
Profit margin is calculated with the selling price (or revenue) taken as base times 100. It is the percentage of selling price that is turned into profit. Profit percentages are calculated to find the ratio of profit to cost of an investment. Profit margin is an indicator of a company's pricing strategies and how well it controls costs. Differences in competitive strategy and product mix cause the profit margin to vary among different companies. The profit margin is used mostly for internal comparisons. It is difficult to accurately compare the net profit ratio for different entities. Individual businesses' operating and financing arrangements vary so much that different entities are bound to have different levels of expenditure, so that comparison of one with another can have little meaning. A low profit margin indicates a low margin of safety: higher risk that a decline in sales will erase profits and result in a net loss, or a negative margin.
Margine di profitto di aziende nel Health Care settore su OTC rispetto a Akorn
Cosa fa Akorn?
Akorn, Inc., a specialty pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Further, the company sells its products to wholesale distributors. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois. On May 20, 2020, Akorn, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Aziende con margine di profitto simili a Akorn
- Schrole Ltd ha Margine di profitto di -33.39%
- Beken ha Margine di profitto di -33.38%
- Acreage ha Margine di profitto di -33.36%
- Janison Education ha Margine di profitto di -33.36%
- Anaplan Inc ha Margine di profitto di -33.25%
- 268 ha Margine di profitto di -33.25%
- Akorn ha Margine di profitto di -33.23%
- OFS Credit ha Margine di profitto di -33.21%
- OFS Credit ha Margine di profitto di -33.21%
- OFS Credit ha Margine di profitto di -33.21%
- OFS Credit ha Margine di profitto di -33.21%
- OFS Credit ha Margine di profitto di -33.21%
- OFS Credit ha Margine di profitto di -33.21%